On Feb. 10, 2022, Vir Biotech announced that preclinical data suggested that sotrovimab, an investigational monoclonal antibody authorized for emergency use in the U.S. and developed in conjunction with GlaxoSmithKline, retains neutralizing activity against the BA.2 subvariant of Omicron.

These pseudovirus results were shared with government and regulatory authorities around the world. The Company published the data on bioRxiv.